Cargando…
Comment on “Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity” Antioxidants 2020, 9, 594
Autores principales: | Stehr, Jan Eric, Lundström, Ingemar, Karlsson, Jan Olof G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555808/ https://www.ncbi.nlm.nih.gov/pubmed/32872241 http://dx.doi.org/10.3390/antiox9090802 |
Ejemplares similares
-
Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity
por: Canta, Annalisa, et al.
Publicado: (2020) -
Reply to a Comment Paper on the Published Paper by Canta, A. et al: “Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity”—Antioxidants 2020, 9, 594
por: Canta, Annalisa, et al.
Publicado: (2020) -
Evidence that fodipir (DPDP) binds neurotoxic Pt(2+) with a high affinity: An electron paramagnetic resonance study
por: Stehr, Jan Eric, et al.
Publicado: (2019) -
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
por: Karlsson, Jan Olof G.
Publicado: (2019) -
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
por: Karlsson, Jan Olof G., et al.
Publicado: (2019)